MD1003 is under clinical investigation and has not been approved by regulatory authorities (including FDA and EMA).


About this program

MedDay’s lead candidate, MD1003, is a patented oral formulation of high dose Pharmaceutical grade Biotin (hdPB) in development in progressive forms of Multiple Sclerosis.
MD1003 is also currently being evaluated in other neurodegenerative diseases.
For more information on ongoing trials, visit


Learn more about the metabolic approach in progressive forms of Multiple Sclerosis 


About MD1003 Phase III trials

Clinical development of this product is proceeding and MedDay is currently conducting a placebo-controlled phase III trial.
For more information on SPI2 trial, visit

Expanded Access policy (US only)

Learn more about MedDay’s Expanded Access policy (United States only)